Study Evaluating rhBMP-2/CPM in Closed Distal Radius Fractures
Study Details
Study Description
Brief Summary
To evaluate the safety of rhBMP-2/CPM administered to subjects presenting with closed distal radius fractures. The key safety variables comprising this assessment are: 1) incidence of delayed union; 2) median time to fracture union (assessed by the investigators); 3) incidence of local neurovascular events (those involving the region under study [RUS]); and 4) rate of fracture displacement. The primary objective will be met if these outcomes in the active and placebo treatment groups are at least comparable to those of the SOC control group.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Outcome Measures
Primary Outcome Measures
- Determine the safety of administering rhBMP-2/CPM to subjects with distal radius fractures that require surgical fixation. []
Secondary Outcome Measures
- Feasibility of the test article injection procedure and localization of the test article relative to the distal radius fracture site. []
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adults aged 50 to 80 years of age; alert and oriented to person, place, and time.
-
Acute, closed distal radius fractures (within 4 cm of the tip of the radial styloid process), classified according to AO/ASIF as either A2 or A3 (extra-articular) or C1 or C2 (intra-articular) fractures.
-
Closed fracture reduction and definitive fracture fixation performed within 7 days after injury by means of external skeletal and/or percutaneous pin fixation. Note: fractures that are initially treated by closed reduction and casting, then converted to external or percutaneous pin fixation for definitive fracture fixation within 7 days after injury are eligible for the study.
Other inclusion applies.
Exclusion Criteria:
-
Other fractures of the ipsilateral upper extremity (except for ulnar styloid fractures) or the contralateral upper extremity (except for previously healed fractures without residual functional deficit).
-
Fracture fixation by other means (eg, plate and screw fixation).
-
Planned treatment for the fracture includes any procedure to promote fracture healing (eg, open reduction internal fixation, bone grafting, non-invasive modalities such as ultrasound, electrical stimulation, etc). Note: After 12 weeks have elapsed since administration of the treatment assignment, unanticipated procedures to promote fracture healing are permitted as clinically indicated.
Other exclusion applies.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Kuopio | Finland | 70211 | ||
| 2 | Oulu | Finland | 70211 | ||
| 3 | Turku | Finland | 20520 | ||
| 4 | Creteil | France | 94010 | ||
| 5 | Paris | France | 75012 | ||
| 6 | Paris | France | 75651 | ||
| 7 | Paris | France | 75970 |
Sponsors and Collaborators
- Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
- Study Director: Medical Monitor, Wyeth is now a wholly owned subsidiary of Pfizer
- Principal Investigator: Trial Manager, For Finland, MedInfoNord@wyeth.com
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 3100N7-114